Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
83 hedge funds and large institutions have $75.3M invested in Sorrento Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 9 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
37% more call options, than puts
Call options by funds: $1.57M | Put options by funds: $1.15M
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
1% less funds holding
Funds holding: 84 → 83 (-1)
31% less capital invested
Capital invested by funds: $109M → $75.3M (-$33.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$7.53M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$5.04M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.38M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.61M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$352K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$333K |
| 3 |
Morgan Stanley
New York
|
-$330K |
| 4 |
D.E. Shaw & Co
New York
|
-$324K |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$250K |
SRNE Hedge Fund Activity: Q2 2019 in Review
83 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q2 2019, worth a combined $75.3M — down 31% from $109M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SRNE positions and 9 closed out — a net gain of 1 holder — while 32 added to existing stakes and 18 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $7.53M. The largest seller was Deutsche Bank, cutting an estimated $352K.
- 83 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q2 2019, down from 84 in Q1 2019.
- Funds reported $75.3M of Sorrento Therapeutics, Inc. stock for Q2 2019, down 31% quarter-over-quarter.
- 10 funds opened new Sorrento Therapeutics, Inc. positions in Q2 2019 and 9 closed out, a net change of +1 holder.
- The largest Sorrento Therapeutics, Inc. buyer in Q2 2019 was Deerfield Management, an estimated $7.53M added.
- The largest Sorrento Therapeutics, Inc. seller in Q2 2019 was Deutsche Bank, an estimated $352K sold.
Based on aggregated 13F filings for Q2 2019.